HIGH-DOSE AND SUSTAINED DELIVERY OF HIV-1 BROADLY NEUTRALIZING ANTIBODIES VIA SUBCUTANEOUS INJECTION OF HYDROGEL-BASED MICROPARTICLE FORMATIONS

Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV-1 Broadly Neutralizing Antibodies: NIAID and its partners are building on the success of the Antibody Mediated Prevention (AMP) trials by engineering next-generation broadly neutralizing antibody (bNAb) candidates to enhance potency, increase tissue levels, extend half-life, and contend with the ever-evolving global diversity of HIV-1. Developing bNAb cocktails presents additional challenges: complex pharmacokinetics, larger injection volumes, multi-product formulations, and complicated manufacturing. The goal of this program is to support small businesses in the development of devices and/or materials for administration of HIV-1 bNAb(s) and bNAb derivatives (e.g., bispecific antibodies), resulting in increased protection from infection. The goal of this contract is to generate a sustained-release formulation of VRC01 using acoustophoretic printing of hydrogel microparticles (HMP).